Pharmaceutical companies share significant concerns over their ability to bring more drugs to market faster due to clinical data challenge
|
REDWOOD SHORES, Calif., /PRNewswire/ -- Pharmaceutical companies share significant concerns over their ability to bring more drugs to market faster due to clinical data challenges. A new global study, commissioned by Oracle Health Sciences and conducted by Pharma Intelligence, revealed that 57 percent of the clinical researchers surveyed believe that their clinical data issues result in trial delays. In addition to trial delays, 81 percent of respondents cited data governance issues as the biggest challenge in meeting regulatory compliance. The top three data issues according to survey respondents were duplicate data/inconsistent data, data quality and data integrity/traceability. "Data governance is our top concern because clinical data quality issues can hinder a trial's completion," said Melonie Longan, Director, Data Operations, Functional Services, Premier Research. Premier Research is a CRO serving biotechnology customers who are researching therapies related to analgesia, dermatology, hematology, oncology, neuroscience, pediatrics, and rare disease. When asked what the top three operational challenges were with their clinical trial data, 51 percent cited data completeness, 45 percent said data quality and 43 percent, data cleaning. "The kind of clinical data quality issues such as those highlighted in this report can have significant negative impacts," said Julie Barenholtz, Principal Clinical Data Manager, Cytel Inc. "As a data company, we are always looking for ways to improve the quality of the data and process it efficiently so that patients have access to treatments as quickly as possible." Founded in 1987, Cytel is a multinational contract research organization (CRO) known for its pioneering work in statistical science and the design and implementation of adaptive clinical trials. Not surprisingly, over three-fourths of respondents cited inconsistent data and missing patient data as the most critical clinical data problems to catch in clinical trials. "Clinical teams are forced to spend time cleaning data instead of analyzing it, and they can't always see the entire picture of what is available to them, this delays the ability to make critical decisions about the trial and holds up regulatory submission," said Steve Rosenberg, General Manager, Oracle Health Sciences. "Clinical researchers shouldn't have to spend time and resources on fixing data issues that technology was built to handle. Technology can, and should, be used to eliminate unnecessary manual intervention and mitigate risk so we can get therapies in the hands of patients who are waiting." The top three risks highlighted by the research include the need for additional data reconciliation; incomplete data to determine efficacy and patient replacements. "Wasting precious time reconciling clinical data issues can be detrimental and costly to our customers," said Vicki Gashwiler, Associate Director, Strategic Development & Market Access, MedTech Division for Novella Clinical. "Our top concern is proactive data management and data monitoring to reduce the risk of clinical data quality issues slowing down a trial. These delays can have significant financial implications for our customers." About the Survey Additional Resources
About Oracle About Oracle Health Sciences Trademarks
View original content to download multimedia:http://www.prnewswire.com/news-releases/survey-lack-of-confidence-in-clinical-trial-data-delaying-drug-development-300717091.html SOURCE Oracle |
||
Company Codes: NYSE:ORCL |
